The 33 references in paper Gerald Schulman, R. Vanholder ., T. Niwa ., Д. Шулман ., Р. Ванхолдер ., Т. Нива . (2015) “AST-120: контроль над прогрессированием хронической болезни почек // AST-120 for the management of progression of chronic kidney disease” / spz:neicon:nefr:y:2015:i:1:p:21-29

1
Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4(8):1293–1301
(check this in PDF content)
2
US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011
(check this in PDF content)
3
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375(9731):2073–2081
(check this in PDF content)
4
Vanholder R, Massy Z, Argiles A et al. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048–1056
(check this in PDF content)
5
KDOQI. KDOQI clinical practice guidelines and clinical practice rec ommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–S154
(check this in PDF content)
6
Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010;20(Suppl 5):S2–S6
(check this in PDF content)
7
Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimu lates the progression of glomerular sclerosis. J Lab Clin Med. 1994;124(1):96–104
(check this in PDF content)
8
Barreto FC, Barreto DV, Liabeuf S, et al; European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–1558
(check this in PDF content)
9
Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant. 2013;28(1):70–78
(check this in PDF content)
10
Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One. 2012;7(3):e34026
(check this in PDF content)
11
Kim SH, Yu MA, Ryu ES et al. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest. 2012;92(4):488–498
(check this in PDF content)
12
Bolati D, Shimizu H, Higashiyama Y et al. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol. 2011;34(4):318–323
(check this in PDF content)
13
Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. J Ren Nutr. 2012;22(1):176–180
(check this in PDF content)
14
Shimizu H, Hirose Y, Goto S, et al. Indoxyl sulfate enhances angio tensin II signaling through upregulation of epidermal growth fac tor receptor expression in vascular smooth muscle cells. Life Sci. 2012;91(5–6):172–177
(check this in PDF content)
15
Shimizu H, Bolati D, Adijiang A, et al. NF-κB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression and inhibition of proliferation in proximal tubular cells. Am J Physiol Cell Physiol. 2011;301(5):C1201–C1212
(check this in PDF content)
16
Masai N, Tatebe J, Yoshino G, Morita T. Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor-κB. Circ J. 2010;74(10):2216–2224
(check this in PDF content)
17
Shimizu H, Bolati D, Adijiang A, et al. Indoxyl sulfate downregulates renal expression of Klotho through production of ROS and activation of nuclear factor-kB. Am J Nephrol. 2011;33(4):319–324
(check this in PDF content)
18
Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012;81(7):640–650
(check this in PDF content)
19
Niwa T, Emoto Y, Maeda K et al. Oral sorbent suppresses accumulation of albumin-bound indoxyl sul phate in serum of haemodialysis patients. Nephrol Dial Transplant. 1991;6(2):105–109
(check this in PDF content)
20
Kanai F, Takahama T, Yamazaki Z et al. Effects of oral adsorbent on experimental uremic rats. Nihon Jinzo Gakkai Shi. 1986;28(9):1249–1259
(check this in PDF content)
21
Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997;23(3–6):179–184
(check this in PDF content)
22
Niwa T, Nomura T, Sugiyama S et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl. 1997;62:S23–S28
(check this in PDF content)
23
Shoji T, Wada A, Inoue K, et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kid ney disease patients with moderate decrease in renal function. Nephron Clin Pract. 2007;105(3):c99– c107
(check this in PDF content)
24
Nakamura T, Sato E, Fujiwara N, et al. Oral adsorbent AST120 amelio rates tubular injury in chronic renal failure patients by reducing proteinu ria and oxidative stress generation. Metabolism. 2011;60(2):260–264
(check this in PDF content)
25
Konishi K, Nakano S, Tsuda S et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract. 2008;81(3):310–315
(check this in PDF content)
26
Akizawa T, Asano Y, Morita S, et al; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54(3):459–467
(check this in PDF content)
27
Marier JF, Lee J, Kambhampati SR, et al. Effect of repeated oral admin istrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease. Am J Nephrol. 2006;26(2):136–141
(check this in PDF content)
28
Schulman G, Agarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis. 2006;47(4):565–577
(check this in PDF content)
29
Maeda K, Hamada C, Hayashi T, et al. Efficacy of adsorbent in delay ing dialysis initiation among chronic kidney disease patients. Dial Transplant. 2011;40(5):212–216
(check this in PDF content)
30
Ueda H, Shibahara N, Takagi S et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial. 2007;11(3):189–195
(check this in PDF content)
31
Ueda H, Shibahara N, Takagi S et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail. 2008;30(9):856–860
(check this in PDF content)
32
Maeda K, Hamada C, Hayashi T, et al. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res. 2009;37(1):205–213
(check this in PDF content)
33
Hatakeyama S, Yamamoto H, Okamoto A, et al. Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. Int J Nephrol. 2012;2012:376128 Перевод А.Мосикян
(check this in PDF content)